Abstract:AIMS/HYPOTHESIS:An increasing body of evidence has shown that the catabolism of branched-chain amino acids (BCAAs; leucine, isoleucine and valine) is impaired in obese animals and humans, contributing to the development of insulin resistance and type 2 diabetes. Promoting BCAA catabolism benefits glycaemic control. It remains unclear whether BCAA catabolism plays a role in the therapeutic efficacy of currently used glucose-lowering drugs such as metformin.METHODS:Mice were treated with vehicle or metformin (250 mg/kg per day) for more than 4 weeks to investigate the effects of metformin in vivo. In vitro, primary mouse hepatocytes and HepG2 cells were treated with 2 mmol/l metformin. The therapeutic efficacy of metformin in the treatment of type 2 diabetes was assessed in genetically obese (ob/ob) mice and high-fat-diet-induced obese (DIO) mice. Enhancing BCAA catabolism was achieved with a pharmacological agent, 3,6-dichlorobenzo[b]thiophene-2-carboxylic acid (BT2). The ob/ob mice were treated with a low-BCAA diet or intermittent protein restriction (IPR) to reduce BCAA nutritional intake.RESULTS:Metformin unexpectedly inhibited the catabolism of BCAAs in obese mice, resulting in an elevation of BCAA abundance. AMP-activated protein kinase (AMPK) mediated the impact of metformin on BCAA catabolism in hepatocytes. Importantly, enhancing BCAA catabolism via a pharmacological agent BT2 significantly potentiated the glucose-lowering effect of metformin while decreasing circulating BCAA levels in ob/ob and DIO mice. Similar outcomes were achieved by a nutritional approach of reducing BCAA intake. IPR also effectively reduced the circulating BCAA abundance and enhanced metformin's glucose-lowering effect in ob/ob mice. BT2 and IPR treatments reduced the expression of fructose-1,6-bisphosphatase 1, a rate-limiting enzyme in gluconeogenesis, in the kidney but not liver, indicating the involvement of renal gluconeogenesis.CONCLUSIONS/INTERPRETATION:Metformin self-limits its therapeutic efficacy in the treatment of type 2 diabetes by triggering the suppression of BCAA catabolism. Enhancing BCAA catabolism pharmacologically or reducing BCAA intake nutritionally potentiates the glucose-lowering effect of metformin. These data highlight the nutritional impact of protein on metformin's therapeutic efficacy and provide new strategies targeting BCAA metabolism to improve metformin's effects on the clinical outcome in diabetes.

Metformin prevents the pathological browning of subcutaneous white adipose tissue

Direct Delivery of Metformin to Subcutaneous White Adipose Tissue and Brown Adipose Tissue for Combating Obesity

Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro

Metformin Suppresses Lipid Accumulation in Skeletal Muscle by Promoting Fatty Acid Oxidation.

Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes.

Metformin Protects Endothelial Function in Diet-Induced Obese Mice by Inhibition of Endoplasmic Reticulum Stress Through 5′ Adenosine Monophosphate–Activated Protein Kinase–Peroxisome Proliferator–Activated Receptor Δ Pathway

A Role for PFKFB3/iPFK2 in Metformin Suppression of Adipocyte Inflammatory Responses

Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21

Metformin plus L-carnitine enhances brown/beige adipose tissue activity via Nrf2/HO-1 signaling to reduce lipid accumulation and inflammation in murine obesity

Dapagliflozin promotes browning of white adipose tissue through the FGFR1-LKB1-AMPK signaling pathway

Ampk Activation By Metformin Suppresses Abnormal Extracellular Matrix Remodeling In Adipose Tissue And Ameliorates Insulin Resistance In Obesity

Metformin Reduces Lipolysis In Primary Rat Adipocytes Stimulated By Tumor Necrosis Factor-Alpha Or Isoproterenol

Targeting BCAA Metabolism to Potentiate Metformin’s Therapeutic Efficacy in the Treatment of Diabetes in Mice

Role of gut microbial-derived metabolites and other select agents on adipocyte browning

Metformin Inhibits Gluconeogenesis Via a Redox-Dependent Mechanism in Vivo

Metformin increases bone marrow adipose tissue by promoting mesenchymal stromal cells apoptosis

Metformin Ameliorates High Uric Acid-Induced Insulin Resistance in Skeletal Muscle Cells.

Metformin prevents LYRM1-induced insulin resistance in 3T3-L1 adipocytes via a mitochondrial-dependent mechanism.

Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis

Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis

Metformin Attenuates Palmitic Acid-Induced Insulin Resistance In L6 Cells Through The Amp-Activated Protein Kinase/Sterol Regulatory Element-Binding Protein-1c Pathway